MUSSETTI, ALBERTO
MUSSETTI, ALBERTO
Universita' degli Studi di MILANO
CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approach
2023 P. Dreger, P. Corradini, J.G. Gribben, B. Glass, M. Jerkeman, M.J. Kersten, F. Morschhauser, A. Mussetti, A. Viardot, P.L. Zinzani, A. Sureda
Editorial: Novel treatments for diffuse large B-cell lymphoma: The post-CART era
2022 A. Mussetti, E. Derenzini, S. Clementine, A. Sureda
Handling the COVID-19 pandemic in the oncological setting
2020 A. Mussetti, C. Maluquer, A. Albasanz-Puig, C. Gudiol, G. Moreno-Gonzalez, P. Corradini, A. Sureda
Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors
2018 A.M. Carella, P. Corradini, A. Mussetti, U. Ricardi, U. Vitolo, S. Viviani
Ocular disorders in multiple myeloma patients: cross-sectional study of prevalence and association with treatment
2018 M. Pennisi, L. Berchicci, E. Miserocchi, A. Mussetti, V. Cacioppo, A. David, A. Scialdone, I. Lorusso, G. Modorati, P. Corradini, V. Montefusco
CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide
2018 A. Mussetti, C. de Philippis, C. Carniti, M. Bastos-Oreiro, J. Gayoso, N. Cieri, M. Pennisi, F. Ciceri, R. Greco, J. Peccatori, F. Patriarca, J. Mariotti, L. Castagna, P. Corradini
Haploidentical allogeneic hematopoietic cell transplantation for multiple myeloma using post transplant cyclophosphamide GVHD prophylaxis
2017 L. Castagna, A. Mussetti, R. Devillier, A. Dominietto, M. Marcatti, G. Milone, F. Maura, C. de Philippis, B. Bruno, S. Furst, D. Blaise, P. Corradini, V. Montefusco
Next-generation sequencing of a family with a high penetrance of monoclonal gammopathies for the identification of candidate risk alleles
2017 N. Bolli, M. Barcella, E. Salvi, F. D'Avila, A. Vendramin, C. De Philippis, N.C. Munshi, H. Avet Loiseau, P.J. Campbell, A. Mussetti, C. Carniti, F. Maura, C. Barlassina, P. Corradini, V. Montefusco
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?
2017 F. Patriarca, L. Giaccone, F. Onida, L. Castagna, B. Sarina, V. Montefusco, A. Mussetti, N. Mordini, E. Maino, R. Greco, J. Peccatori, M. Festuccia, F. Zaja, S. Volpetti, A. Risitano, R. Bassan, P. Corradini, F. Ciceri, R. Fanin, M. Baccarani, A. Rambaldi, F. Bonifazi, B. Bruno
Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis : where do we stand?
2017 A. Mussetti, R. Greco, J. Peccatori, P. Corradini
Allogeneic Stem Cell Transplantation for Relapsed/Refractory B-Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial Including Rituximab in the Reduced Intensity Conditioning Regimen
2017 A. Dodero, F. Patriarca, G. Milone, B. Sarina, R. Miceli, A. Iori, F. Barretta, E. Terruzzi, A. Mussetti, M. Pini, A. Bosi, A. Dominietto, N. Cascavilla, F. Onida, F. Narni, L. Farina, A. Rambaldi, P. Corradini
Recurrent Hodgkin lymphoma : toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agents
2015 A. Pinto, P. Corradini, A. Mussetti, P.L. Zinzani
Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation
2013 V. Montefusco, F. Spina, F. Patriarca, M. Offidani, B. Bruno, M. Montanari, A. Mussetti, A. Sperotto, I. Scortechini, A. Dodero, R. Fanin, P. Valagussa, P. Corradini